Psoriasis: Update Bulletin #3 [April 2018]
This edition presents key opinion leader (KOL) views on recent developments in the treatment of psoriasis. Topics covered include; KOL views on AbbVie’s presentation of positive results from two pivotal Phase III trials with interleukin-23 (IL-23) inhibitor risankizumab, including head-to-head data with competitor Stelara (ustekinumab; Janssen Biotech); KOL views on the Food and Drug Administration’s (FDA) approval of second-in-class interleukin-23 (IL-23) inhibitor Ilumya (tildrakizumab; Sun Pharmaceuticals) in March 2018; and views on two orally administered novel therapies for the treatment of moderate-to-severe psoriasis, including Bristol Myers Squibb’s tyrosine kinase 2 (Tyk2) inhibitor BMS-986165 and MetrioPharm’s macrophage modulator MP1032.
In February 2018, AbbVie presented positive results from the UltiMMa-1 and UltiMMa-2 Phase III clinical trials, illustrating the superiority of interleukin-23 (IL-23) inhibitor risankizumab compared with marketed biological therapy Stelara (ustekinumab; Janssen Biotech), but how do key opinion leaders perceive the data from these pivotal trials?
If approved, how can risankizumab differentiate itself from an increasingly crowded market populated with efficacious biological therapies?
How and where in the treatment paradigm for moderate-to-severe psoriasis will risankizumab be used?
How do key opinion leaders perceive Sun Pharmaceuticals’ second-in-class IL-23 inhibitor Ilumya (tildrakizumab)?
Ilumya met the primary endpoints in the reSURFACE Phase III development program, but are the results sufficient to establish this product as a viable competitor to marketed biological therapies for the treatment of moderate-to-severe psoriasis?
Bristol Myers Squibb’s BMS-986165 represents a novel approach in the treatment of moderate-to-severe psoriasis, targeting tyrosine kinase 2 (Tyk2), but how viable do opinion leaders consider this mechanism of action, and what concerns if any do they have about inhibiting this pathway?
If approved, where in the treatment paradigm will BMS-986165 sit, and what products will it compete with?
How do opinion leaders view MetrioPharm’s novel macrophage targeting therapy MP1032 in the treatment of moderate-to-severe psoriasis?
As MP1032 moves into Phase IIb development, how optimistic are opinion leaders with regard to the potential of this product?